Q-omics provides the consensus-scored TENM3 profile across patient tissues and cancer cell-line models. TENM3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TENM3 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TENM3 RNA expression shows 18,214 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where TENM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TENM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TENM3 survival associations across molecular data types. TENM3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TENM3 RNA expression–survival associations across cancer types. High TENM3 expression shows unfavorable associations in MESO, OV, BLCA, STAD and SARC, but favorable associations in CHOL. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TENM3 RNA expression.
This table summarizes TENM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TENM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TENM3 shows lower tumor expression in THCA, BRCA and LIHC and higher tumor expression in HNSC, LUAD and LUSC. The HNSC box plot shows higher TENM3 RNA expression in tumor versus normal tissue (log2 FC = +3.080, t-test p < 0.001).
This table shows molecular features associated with TENM3 in patient tissues and cancer cell lines. In patient samples, TENM3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TENM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
